Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Dow
Baxter
Medtronic
Colorcon

Last Updated: August 8, 2022

Investigational Drug Information for RPL554


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug RPL554?

RPL554 is an investigational drug.

There have been 10 clinical trials for RPL554. The most recent clinical trial was a Phase 2 trial, which was initiated on February 8th 2017.

The most common disease conditions in clinical trials are Lung Diseases, Pulmonary Disease, Chronic Obstructive, and Lung Diseases, Obstructive. The leading clinical trial sponsors are Verona Pharma plc, Iqvia Pty Ltd, and Cystic Fibrosis Trust.

There are thirty-one US patents protecting this investigational drug and four hundred international patents.

Recent Clinical Trials for RPL554
TitleSponsorPhase
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPDIQVIAPhase 2
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPDIqvia Pty LtdPhase 2
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPDLGC LimitedPhase 2

See all RPL554 clinical trials

Clinical Trial Summary for RPL554

Top disease conditions for RPL554
Top clinical trial sponsors for RPL554

See all RPL554 clinical trials

US Patents for RPL554

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RPL554 See Plans and Pricing Inhalable pharmaceutical compositions iCeutica Pty Ltd. (Iluka, WA, AU) See Plans and Pricing
RPL554 See Plans and Pricing JAK inhibitors containing a 4-membered heterocyclic amide THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
RPL554 See Plans and Pricing Fused imidazo-piperidine JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
RPL554 See Plans and Pricing Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE) See Plans and Pricing
RPL554 See Plans and Pricing Chemical compounds AstraZeneca AB (Sodertalje, SE) See Plans and Pricing
RPL554 See Plans and Pricing Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition NITTO DENKO CORPORATION (Osaka, JP) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RPL554

Drugname Country Document Number Estimated Expiration Related US Patent
RPL554 Australia AU2013227351 2032-02-28 See Plans and Pricing
RPL554 Australia AU2016202881 2032-02-28 See Plans and Pricing
RPL554 Australia AU2017213466 2032-02-28 See Plans and Pricing
RPL554 Canada CA2865702 2032-02-28 See Plans and Pricing
RPL554 China CN104703584 2032-02-28 See Plans and Pricing
RPL554 China CN107875127 2032-02-28 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Dow
Baxter
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.